clinical trial · NCT02526160
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Kyowa Kirin, Inc.·phase3·completed·n = 134
X-linked HypophosphatemiaburosumabPlacebo
brief summary
The primary efficacy objective of this study is to establish the effect of burosumab treatment compared with placebo on increasing serum phosphorus levels in adults with XLH.
started
Oct 22, 2015
primary completion
Dec 22, 2016
completion
Dec 6, 2018
last updated
Jun 18, 2024
official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol